IMMUNNOTHERAPY FOR CANINE CANCER & SCREENING

What is K9-ACV?

K9-ACV is a Canine Autologous Cancer Vaccine. Using the therapeutic approach of immunotherapy, scientists have developed a cancer vaccine, created personally for your pet that can be incorporated in your pet’s cancer treatment plan. Our hope is that K9-ACV will improve and extend the quality of life for your dog. K9-ACV is designed for all operable tumors.

What is the treatment protocol?

The treatment protocol involves three visits after your pet’s initial surgery. During the treatment protocol your pet will receive an injection just under the skin. The visit is quick and easy, and your pet goes home with you.

How id the vaccine prepared?

Step 1: We will surgically remove tumor or part of tumor and ship it overnight to Ardent laboratory.

Step 2: Ardent lab team will process the tumor sample and extract the tumor cells to prepare 3 dose vaccine.

Step 3: Finished vaccine is shipped overnight back to our hospital and is administered every 30 days.

How successful will the vaccine be on the cancer in your pet?

The vaccine was designed from the success of treating human cancer patients with similar immunotherapy approaches. In a recent publication 85% of patients displayed an increased response against their cancer post vaccination. Clinical success has been marked across many different cancer types. Success should be measured by well-being of your pet.

What side effects could occur?

K9-ACV is not a drug. We do not expect any major side effects to occur. During the first 48 hours, your pet may experience mild fever, sleepiness or loss of appetite. Owners may observe that the vaccine administration sited becomes slightly inflamed with minor redness and swelling near where the vaccine was injected although this is expected to subside quickly.

Ask us today about the benefits of K9-ACV with Ardent Animal HealthNew Paragraph

LIQUID BIOPSY ONCOK9 CANCER SCREENING

PetDX introduces OncoK9, a multi-cancer detection test, designed to detect multiple classes of genomic alterations associated with a wide variety of cancers. This means that with just a blood sample, we can look for a cancer signal originating from many different types of cancer including some of the most common cancers seen in practice: lymphoma, osteosarcoma, hemangiosarcoma, histiocytic sarcoma, mammary gland carcinoma, malignant melanoma, mast cell tumors, soft tissue sarcoma and anal sac adenocarcinoma. In the clinical validation study, OncoK9 detected 30 different cancer types as listed below.